AOD9604 is a fragment of human growth hormone — specifically the last 15 amino acids at one end of the molecule, slightly modified. It was developed by researchers at Monash University in Australia who noticed that growth hormone's fat-burning effects seemed to come primarily from that end of the molecule. The goal was to isolate the fat loss benefits without the blood sugar disruption and tissue growth that comes with using full growth hormone.
It works by binding to the beta-3 adrenergic receptor on fat cells, telling them to release stored fat and burn it for energy. This effect is particularly noticeable in the abdomen and other areas where fat tends to be metabolically stubborn. Crucially, it doesn't raise IGF-1 levels or interfere with insulin, which are the two main concerns with full growth hormone therapy.
The development history makes AOD9604 unusual among research peptides. It was actually taken through full Phase 1, 2, and 3 clinical trials by Metabolic Pharmaceuticals. It passed every safety test and was declared safe for long-term human use. The fat loss results in humans were real but more modest than in animal studies, and the company eventually pivoted toward researching AOD9604 for cartilage repair and osteoarthritis rather than pursuing obesity approval.
In the athletic and wellness community, it's used as a gentle, targeted fat loss tool — typically stacked with other peptides like CJC-1295 or ipamorelin for a broader effect. It's also sold as a food ingredient in some countries due to its clean safety profile, making it one of the more accessible peptides available.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
AOD9604 was first synthesized in the early 2000s at Monash University. The researchers identified that the fat-mobilizing effects of growth hormone mapped to a specific region of the C-terminal end of the molecule and created a modified fragment to isolate those effects.
Preclinical studies in obese mice showed significant fat reduction with no effects on blood sugar or growth. Human trials followed — four Phase 1/2 studies and one Phase 3 trial were completed. The trials confirmed safety and tolerability and showed modest but real reductions in body fat, particularly visceral fat.
The clinical program stalled because the effect size wasn't large enough to differentiate it in the obesity drug market against competing pharmaceutical options at the time. The company then redirected research toward its apparent benefits for articular cartilage, which were observed as a secondary finding.
In 2014, the FDA granted AOD9604 GRAS (Generally Recognized as Safe) status, allowing it to be used as a food additive. This is an unusual status for a peptide and reflects the depth of safety data that was collected during pharmaceutical development.
mild results. lost maybe 1.5kg of fat over 10 weeks. no sides at all which is nice but i was hoping for more. probably better as part of a stack than solo.
probably the most side effect free thing i've ever taken. no noticeable effects for the first 6 weeks then my waist measurement quietly started dropping. patience required.
subtle but real. belly fat has gone down over 12 weeks stacked with cjc and ipa. wouldn't know it was working if i wasn't tracking measurements.
CJC-1295 is a synthetic version of a hormone your body already produces called GHRH — growth hormone releasing…
IGF-1 LR3 is a modified version of IGF-1 — insulin-like growth factor 1 — a hormone your liver produces in res…
Melanotan 2 is a synthetic version of a hormone your body makes called alpha-MSH, which signals skin cells to…